Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daclatasvir + asunaprevir + BMS-791325 + ribavirin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a four-drug combination regimen consisting of three direct acting antivirals—daclatasvir, asunaprevir, and BMS‑791325—plus the antiviral ribavirin. Daclatasvir is an NS5A replication complex inhibitor; asunaprevir is an NS3 protease inhibitor; and BMS‑791325 is a non-nucleoside NS5B polymerase inhibitor. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity. The combination was developed for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1. Clinical studies have shown that regimens containing these agents can achieve high rates of sustained virologic response in both treatment-naive and previously treated patients, including those with reduced interferon responsiveness[1][2][4][5][6]. Bristol Myers Squibb led development of this investigational regimen.
- Other names
- asunaprevir + daclatasvir + BMS-791325 + ribavirin
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on daclatasvir + asunaprevir + BMS-791325 + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daclatasvir + asunaprevir + BMS-791325 + ribavirin.